What is Elite Pharmaceuticals Inc worth?
With the base-case assumptions below, a discounted cash flow model on Elite Pharmaceuticals Inc's reported free cash flow gives $0.70 per share. The share price was $0.25 on September 28, 2026, 64% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $0.44 | +75% |
| Base | 15.0% | 9.0% | $0.70 | +179% |
| Bull | 20.0% | 8.0% | $1.18 | +372% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $0.89 | $0.96 | $1.03 | $1.12 | $1.24 |
| 8.0% | $0.75 | $0.79 | $0.83 | $0.89 | $0.96 |
| 9.0% | $0.64 | $0.67 | $0.70 | $0.73 | $0.78 |
| 10.0% | $0.56 | $0.58 | $0.60 | $0.62 | $0.65 |
| 11.0% | $0.49 | $0.51 | $0.52 | $0.54 | $0.56 |
Where the presets come from
Base: years 1 to 5 grow at Elite Pharmaceuticals Inc's revenue growth rate over the last 5 fiscal years (42.4% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions